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Antibiotic resistance is a major public health threat worldwide. In particular, about 80% of cystic ﬁbrosis
patients have chronic Pseudomonas aeruginosa (PA) lung infection resistant to many current antibiotics.
We are therefore developing a novel class of antivirulence agents, quorum sensing inhibitors (QSIs),
which inhibit bioﬁlm formation and sensitize PA to antibiotic treatments. For respiratory conditions,
targeted delivery to the lung could achieve higher local concentrations with reduced risk of adverse
systemic events. In this study, we report the pharmacokinetics of 3 prototype QSIs after pulmonary
delivery, and the simultaneous analysis of the drug concentration-time proﬁles from bronchoalveolar
lavage, lung homogenate and plasma samples, using a pharmacometric modeling approach. In addition
to facilitating the direct comparison and selection of drug candidates, the developed model was used for
dosing simulation studies to predict in vivo exposure following different dosing scenarios. The results
show that systemic clearance has limited impact on local drug exposure in the lung after pulmonary
delivery. Therefore, we suggest that novel QSIs designed for pulmonary delivery as targeted treatments
for respiratory conditions should ideally have a long residence time in the lung for local efﬁcacy with
rapid clearance after systemic absorption for reduced risk of systemic adverse events.
© 2019 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Antibiotic resistance is a growing challenge and a major public
health threatworldwide. In particular, Pseudomonas aeruginosa (PA)
exhibits high rates of resistance to many of the currently available
antibiotic therapies.1,2 Previous reports have indicated that about
80% of patients with cystic ﬁbrosis (CF) have chronic PA lung in-
fections.3,4 New treatment options for these infections are therefore
urgently required. Because the formation of a bioﬁlm increases the
tolerance of PA to antibacterial drugs,5-7 inhibition of the PA
quorum-sensing (QS) signaling pathway, which regulates multipleone: þ46-18-471 4118).
(C.A.S. Bergstr€om).
Inc. on behalf of the American PhaPAvirulence factors aswell as bioﬁlm formation, has been suggested
as a promising target.2,8-11We are therefore developing a novel class
of antivirulence agents, quorum sensing inhibitors (QSIs), with the
aim of sensitizing PA bioﬁlms to antibiotic treatment.
For respiratory conditions such as lung infections, targeted de-
livery of drugs directly to the site of action could provide unique
beneﬁts compared to systemic administration. Local delivery to the
lungcould achieveahigher local concentrationat the target sitewith
reduced systemic exposure and risk of adverse events.12 However,
despite the increasing interest in pulmonary delivery over the last
few decades, compared to conventional oral dosage forms, the
pharmacokinetics (PK) of drug molecules after pulmonary admin-
istration remains relatively poorly understood. Although plasma
drug concentrations are commonly measured for estimating sys-
temic drug exposure, the measurement of drug levels in the lung isrmacists Association®. This is an open access article under the CC BY-NC-ND license
Figure 1. The structure of SEN001 with the numbers indicating the site of
modiﬁcations.
Table 1
The Physicochemical Properties of SEN001, SEN019, and SEN032
Compound MW pKa Log P HBD HBA Tm (C) DH (J/g)
SEN001 321.85 3.29 5.11 1 3 79.7 136.2
SEN019 369.81 1.82 2.35 1 5 176.5 97.4
SEN032 319.81 2.89; 1.54 2.92 0 3 113.1 104.6
HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; MW, molecular weight
in g/mol; Tm, onset melting temperature; DH, melting enthalpy.
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labor-intensive sampling techniques and uncertainties in concen-
tration determination methods. Consequently, there is no common
standard in the sampling and measurement of lung PK.
In the literature, antibiotic concentrations in the lung have been
measured in samples collected from bronchoalveolar lavage (BAL),
sputum, microdialysis, and lung tissue homogenates.13-18 However,
these different sampling methods do not necessarily provide the
same information. For instance, BAL and sputum samples are more
likely to reﬂect extracellular drug concentrations, on the surface of
the airways, whereas microdialysis samples are more likely to
represent drug concentrations at a speciﬁc site of the lung paren-
chyma. In contrast, lung homogenates serve to provide a general
estimation of total drug amounts in the lung and include both
intracellular and extracellular drugs, with no indication of the
speciﬁc site in the lung that was exposed to the drug delivery
system. Although lung PK have been studied using one of these
sampling approaches (i.e., BAL, sputum, lung homogenates, or
microdialysis), to the best of our knowledge, few studies in the
literature, if any, have collected and simultaneously analyzed drug
concentrations in 3 sampling matrices (i.e., BAL, lung tissue ho-
mogenate, and plasma samples) from the same animals using a
mathematical modeling approach to characterize the distribution
of drugs between these physiological compartments.
In this study, we report the simultaneous modeling and anal-
ysis of drug concentrations in plasma and lung, with or without
BAL sampling, of 3 prototype QSIs following pulmonary adminis-
tration. SEN001 is a prototype QSI, which antagonizes the action of
PqsR, a lysR-type regulator of the alkyl-quinolone (AQ)-dependent
QS signaling system in PA, with promising in vitro activity.19
SEN019 and SEN032 are newly designed structural analogues of
SEN001, which also antagonize PqsR and hence inhibit QS. These
compounds were studied in vivo to investigate their therapeutic
potential and suitability as drug candidates. The PK of the com-
pound series following pulmonary administration was studied in
rats, and the observed concentrations were simultaneously
analyzed and modeled. The study demonstrated the use of phar-
macometric modeling as a powerful tool to inform drug candidate
selection in preclinical drug development of treatments for pul-
monary delivery. During the analysis, a pharmacokinetic model
was developed to describe all available observations from the
compound series, and the estimated parameters provided quan-
titative insights into the distribution and clearance properties of
the 3 QSI compounds. Furthermore, the model was able to quan-
tify drug amounts in the lung before BAL collection, thus allowing
direct comparison of local lung exposures between compounds,
with or without BAL sampling. The developed model was then
used to predict in vivo exposure following different dosing regi-
mens to support the design of pharmacodynamics studies in dis-
ease models. The potential impact of systemic clearance on lung
exposure to the drugs following pulmonary administration was
also investigated.
Materials and Methods
Compounds
SEN001 (3-amino-7-chloro-2-nonylquinazolin-4(3H)-one),19
SEN019, and SEN032 are PqsR antagonists developed at the Uni-
versity of Nottingham. SEN001 and SEN019 were synthesized in
house, whereas SEN032 was purchased from Enamine Ltd (Kiev,
Ukraine). The structure of SEN001 is shown in Figure 1. SEN019 and
SEN032 are structural analogues of SEN001, and the sites of
modiﬁcation from SEN001 are indicated with small numbers in
Figure 1. The structures of SEN019 and SEN032 are not disclosed forintellectual property protection purposes because the compounds
are patent-pending. Polyethylene 400 (PEG400) and polysorbate 80
(PS80) were purchased from Sigma-Aldrich (Stockholm, Sweden).
Compound Characterization
Measurements of melting point (Tm) of the compounds were
performed by differential scanning calorimetry (DSC) using a DSC
Q2000 (TA instrument), which was calibrated for temperature and
enthalpy using indium. The instrument was equipped with a
refrigerated cooling system. Tmwas determined using an amount of
1-3 mg in nonhermetic sealed aluminum pans. The compounds
were scanned at a heating rate of 10C/min under a continuously
purged dry nitrogen atmosphere (50 mL/min). Additional physi-
cochemical properties were obtained in silico using ADMET Pre-
dictor Version 7.2 (Simulation Plus, Inc., Lancaster, CA). Two-
dimensional SDF ﬁles of SEN001, SEN019 and SEN032, were intro-
duced into the software, which evaluated the structures to calculate
physiochemical and biopharmaceutical properties at pH 7.4. The
physicochemical properties of the compound series are summa-
rized in Table 1.
Solubility Determination
The equilibrium solubility of the crystalline compounds in
various media was determined by adding excess of the solid
compounds (2-3 mg) to 1 mL (or equivalent proportion) of either
water or PP2% (a mixture of PS80 2% w/w and PEG400 2% w/w in
water). Samples were incubated at 37C for >24 h to allow
dissolution. The supernatant was separated from the excess solid
by centrifugation at 30,279  g for at least 20 min (Heraeus
Megafuge 8R Centrifuge with a MicroClick 24  2 mL rotor). The
concentration of the compound in the supernatant was then
determined by high-performance liquid chromatography with
ultraviolet-detection (HPLC-UV).
Metabolic Stability
Brieﬂy, metabolic stability of the compounds was determined in
0.5 mg/mL human liver microsomes at a compound concentration
of 1 mM in 100mMKPO4 buffer, pH 7.4, in a total incubation volume
of 500 mL. The reactionwas initiated by addition of 1mMNADPH. At
various incubation times (i.e., 0, 5, 10, 20, 40, and 60 min), a sample
T. Sou et al. / Journal of Pharmaceutical Sciences 108 (2019) 630-640632waswithdrawn from the incubation, and the reaction in the sample
was terminated by addition of cold acetonitrile. The amount
of parent compound remaining was analyzed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS).Pharmacokinetic Studies
The PK data of the compound series were collected from a
number of studies in rats (male; Sprague-Dawley). The PK study of
SEN001 was performed at Laval University in Quebec, Canada. The
PK study of SEN019 and SEN032 was performed at XenoGesis
(Nottingham, UK) and its animal research facility Saretius (Not-
tingham, UK). The study protocols were reviewed and approved by
the respective animal ethics committee at Laval University and
Saretius. The animals were carefully monitored throughout the
studies for signs of toxicity.
The drugs were given via intratracheal (IT) administration to the
lungs. Brieﬂy, for SEN001, rats were lightly anesthetized with
gaseous isoﬂurane and placed in a supine position on a restraining
board angled at approximately 60 to 70 from the horizontal. The
tongue of the rat was gently pulled outward using forceps, Q-tips,
and the blade of a small animal otoscope (Hallowel EMC, Pittsﬁeld,
MA) was positioned in the distal part of the mouth to enable
visualization of the vocal cords. An adapted 2 inches 16G intrave-
nous catheter was then maneuvered past the vocal cords to the
trachea-bronchus bifurcation. A 250 mL aliquot of the dosing solu-
tion was then administered into the lungs. Following IT adminis-
tration, the rats were returned to metabolic cages where they
rapidly recovered from the isoﬂurane anesthesia. The study of
SEN019 and SEN032 was performed based on a similar protocol.
The animals were administered SEN001, SEN019, and SEN032 at
doses of 0.067 mg/kg, 0.12 mg/kg, and 0.28 mg/kg of body weight,
respectively. The selection of doses was restricted by the aqueous
solubility and availability of the compounds at the time. Blood,
lung, and BAL samples were collected at predetermined time
points, and the samples were analyzed by LC-MS. A summary of the
PK study design is shown in Table 2.Analytical Methods
For the solubility studies, the concentrations of the compounds
in the samples were analyzed using an Agilent 1290 HPLC system
(Agilent Technologies, Santa Clara, CA) equipped with a UV/Vis
spectrometer DAD detector. The compounds were separated using
an Agilent ZORBAX Eclipse XDB-C18, 3.5 mm, 4.6  100 mm. The
column temperature was set to 50C with a total run time of 4
(SEN019, SEN032) or 7 min (SEN001). The mobile phase was 80% v/
v acetonitrile and 20% v/v water (SEN001, SEN032) or 70% v/v
acetonitrile and 30% v/v water (SEN019), and the ﬂow rate was 1
mL/min using an isocratic method. Absorbance of the compounds
was monitored at 280 nm. The injection volume was 20 mL. Stan-
dard solutions were prepared by dissolving mixtures of the com-
pounds in acetonitrile and analyzed with HPLC to prepare a
calibration curve.Table 2
Summary of the Design of the Pharmacokinetic Studies
Compound N Dose
(mg/kg)
Time Points (h) Sampling
SEN001 21 0.067 0.5, 2, 4, 8, 12, 24, 48 Plasma, lung and BAL
SEN019 18 0.12 0.167, 0.5, 1, 3, 6, 24 Plasma and lung
SEN032 18 0.28 0.167, 0.5, 1, 3, 6, 24 Plasma and lung
BAL, bronchoalveolar lavage; N, number of subjects.For the metabolic stability studies, the amount of parent com-
pound remaining in the microsome samples was analyzed by LC-
MS/MS. Brieﬂy, quantitative analysis was performed using a Wa-
ters XEVO TQ mass spectrometer (MS) in positive electrospray
MRM mode coupled to an Acquity ultraperformance liquid chro-
matography (UPLC) system. The MS ion transitions were SEN001
322/180.1, SEN019 370/111, and SEN032 320/140. The analytes were
separated using a Waters BEH C18 2  50 mm column over a 2-min
run time. The mobile phases were double-distilled water with
formic acid (0.1%) and acetonitrile with formic acid (0.1%).
For the PK study of SEN001, the amounts of the drug in the
samples were quantiﬁed by LC-MS. Brieﬂy, the analyte was
extracted from plasma and lung homogenate samples by solvent
extraction with ethyl acetate. BAL samples were extracted by solid
phase extraction (Waters Oasis MCX extraction cartridges). The
quantitative analysis was conducted using a Shimadzu series 10AD
VP LC system in tandem with an Applied Biosystems Qtrap 4000
hybrid triple-quadrupole linear ion trap mass spectrometer. The
chromatographic separation was achieved using a Phenomenex
Gemini C18 column (3.0 mm, 50 3.0mm). Themobile phases were
0.1% (v/v) formic acid in water and methanol. The MS ion transition
used for analyte detectionwas precursor ion [MþH]þ¼ 322.2m/z,
product ion [M þ H]þ ¼ 180.1 m/z.
For the PK study of SEN019 and SEN032, the amounts of drugs in
the samples were quantiﬁed by LC-MS. Brieﬂy, the plasma and lung
samples were treated with acetonitrile for protein precipitation.
Quantitative analysis was then performed using a Thermo TSQ
Quantiva mass spectrometer in positive electrospray MRM mode
coupled to a Thermo Vanquish UPLC system. MS ion transitions
were SEN019 370/181 and 370/237, and SEN032 320/71 and 320/
140. The analytes were separated using a Phenomenex, Kinetex,
biphenyl 2.6mm, 50  2.1 mm column over a 1.3-min run time. The
mobile phases were Milli-Q water with formic acid (0.1%) and
acetonitrile with formic acid (0.1%).Pharmacokinetic Model Development
The data were ﬁrst analyzed by noncompartmental analysis to
obtain initial estimates. Model development was then performed in
the nonlinear mixed-effects modeling software program NONMEM
(version 7.3, ICON Development Solutions),20 with Perl-speaks-
NONMEM (PsN),21 using the Laplacian conditional estimation
method with interaction algorithm. R (R Foundation for Statistical
Computing, Vienna, Austria) with the Xpose package22 was used for
model evaluation and graphical analysis. Initially, models were
independently developed for SEN001, SEN019, and SEN032 to
obtain key disposition parameters. The observed concentrations
were then combined to simultaneously analyze the pharmacoki-
netic proﬁles of the 3 drugs after IT administration.
The general structural model developed in the analysis is illus-
trated in Figure 2. Brieﬂy, it consists of 1 central lung compartment
(L) where lung homogenate and BAL samples were taken, 1 deep
lung compartment (LP) to describe the disposition of drugs in the
lung before systemic absorption, 1 central plasma compartment (C)
where plasma samples were taken, and 1 peripheral tissue
compartment (P) to describe the disposition of the drugs after
systemic absorption. During the analysis, 1-, 2-, 3-, and 4-
compartment disposition models were evaluated; the transfers of
drug between these compartments over time (t) are shown in
Equations 1-4, where A is the amount of drug in each compartment,
and V, CL, and Q are the volume of distribution, clearance, and
intercompartmental clearance parameters of the corresponding
compartments, respectively.
Table 3
Solubility (mg/mL) of SEN001, SEN019, and SEN032 in Water and the PP2% Formu-
lation (Mean ± s.d., n ¼ 3)
Medium SEN001 SEN019 SEN032
Water <LLOQ 20.2 ± 2.13 15.1 ± 0.34
PP2% 230.6 ± 3.08 182.7 ± 3.42 395.8 ± 3.13
LLOQ, lower limit of quantiﬁcation (1 mg/mL); PP2%, PEG400 2% þ PS80 2% w/w in
water.
Figure 2. Schematic diagram of the general structural model developed for the anal-
ysis. Abbreviations: BAL, bronchoalveolar lavage; CLC, central clearance; CLLP, clearance
from lung to plasma; QC, intercompartmental clearance between VC and VP; QL,
intercompartmental clearance between VL and VLP; VC, volume of the central plasma
compartment; VL, volume of the central lung compartment; VP, volume of the pe-
ripheral tissue compartment; VLP, volume of the deep lung compartment.
Table 4
Metabolic Stability of SEN001, SEN019, and SEN032 in Human Liver Microsomes
Compound Half-Life (min) CLint (mL/min) CLH (mL/min) EH
SEN001 54.4 1491.7 747.9 0.50
SEN019 22.0 3692.1 1066.7 0.71
SEN032 3.3 24,886.7 1414.7 0.94
CLint, intrinsic clearance; ClH, hepatic clearance; EH, hepatic extraction ratio.
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dt
¼ CLLP
VL
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CLLP
VC
$AC 
QL
VL
$AL þ
QL
VLP
$ALP (1)
dAC
dt
¼ CLLP
VL
$AL 
CLLP
VC
$AC 
CLC
VC
$AC 
QC
VC
$AC þ
QC
VP
$AP (2)
dAP
dt
¼ QC
VC
$AC 
QC
VP
$AP (3)
dALP
dt
¼ QL
VL
$AL 
QL
VLP
$ALP (4)
Where BAL samples were available, the addition of a separate
compartment for BAL concentrations was also evaluated but this
was not included in the ﬁnal model. In the ﬁnal model, the total
amount of drug in the central lung compartment represents the
sum of drug amounts in the BAL and lung samples. The concen-
trations of drug in the BAL samples (CBAL) were quantiﬁed by
estimating the fraction of drug collected in BAL (FBAL) from the
amount of drug in the central lung compartment (AL) divided by
the volume of ﬂuid used to collect the BAL samples (VBAL) as shown
in Equation 5.
CBAL ¼
FBAL
VBAL
$AL (5)
During the analysis, the general structural model was devel-
oped and applied to analyze the observed concentrations of the 3
compounds and the ﬁt of various models with and without the
different compartments was evaluated. The volume of the central
lung compartment was ﬁxed to the typical size of lungs in a rat
(2 g) to maintain model identiﬁability. The model parameters
were scaled to the typical weight of the rats (0.3 kg) for
comparability.
Because the majority of samples were terminal samples,
interindividual variability (IIV) of the pharmacokinetic parame-
ters was not estimated. The estimation of both IIV and residual
unexplained variability with good precision requires more than 1
sample per subject. For residual unexplained variability, a mixed
proportional and additive error model and a proportional errormodel were evaluated. Although most observation types were
sufﬁciently well described by the proportional error model, the
plasma concentrations of SEN019 and SEN032 were better
described by the mixed error model. Data below the lower limit
of quantiﬁcation (LLOQ) were handled using the likelihood-based
M3 method.23
The likelihood ratio test was used to evaluate statistical sig-
niﬁcance for inclusion of additional parameters in nested models,
where the objective function value (OFV) is assumed to be c2
distributed. A decrease in OFV of 3.84 between nested models
with 1 parameter difference was considered to be a statistically
signiﬁcant difference at the 5% signiﬁcance level. Model devel-
opment was guided by the biological plausibility of the param-
eter estimates, the change in objective function value (ΔOFV),
parameter precision, and evaluation of diagnostic plots. The ﬁnal
model was evaluated by performing a visual predictive check
(VPC). For the VPC, 1000 data sets were simulated from the ﬁnal
parameter estimates using the original data set as a template. The
predicted medians and their corresponding 95% conﬁdence in-
tervals were computed from the simulation data and overlaid
with the observed values.Drug Exposure Prediction Study
To compare the potential exposure of lung and plasma to various
doses of SEN001, SEN019, and SEN032 following pulmonary
administration, the parameter estimates of the ﬁnal pharmacoki-
netic model were used to perform a dosing simulation study. The
mrgsolve package (version 0.8.12,; Metrum Research Group) in the
software R was used to carry out the simulation. The mean dose in
the PK studies, 0.15 mg/kg, was used to compute the predicted
concentration-time proﬁles for a dose-normalized exposure com-
parison, and drug concentrations were predicted when the com-
pounds were given every 24, 12, and 8 h.
To investigate the potential impact of systemic clearance on lung
and systemic exposures to the drugs, predictions were generated
from a virtual population composed of 1000 simulated data sets
with variability in central clearance (CLC). Since physiological pa-
rameters are typically log-normally distributed, IIV was applied to
CLC using an exponential model, as shown in Equation 6, where CLi
is the individual clearance, CL is the typical clearance of the pop-
ulation, and h is normally distributed with a coefﬁcient of variance
(CV) of 30% around mean 0.
CLi ¼ CL$eh (6)
Figure 3. Visual predictive check of the ﬁnal model showing the observed concentrations of SEN001, SEN019, and SEN032 in plasma, lung, and bronchoalveolar lavage (BAL) with
the observed medians, 2.5th and 97.5th percentiles following intratracheal administration and the corresponding 95% conﬁdence intervals of the predicted medians (shaded).
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Table 5
Parameter Estimates and Relative Standard Errors of the Final Model
Parametera Unitb Description SEN001 % RSE SEN019 % RSE SEN032 % RSE
CLLP L/h Clearanceelung to plasma 0.0175 7 0.0724 1 0.150 10
VL L Volume of distributionecentral lung 0.002 e 0.002 e 0.002 e
CLC L/h Clearanceecentral 0.0745 10 1.11 5 3.74 6
VC L Volume of distributionecentral 0.0855 31 0.583 5 1.51 12
QC L/h Intercompartmental clearanceecentral e e e e 2.35 25
VP L Volume of distributioneperipheral e e e e 1.36 35
QL L/h Intercompartmental clearanceelung 0.00596 37 e e 0.0107 17
VLP L Volume of distributionedeep lung 0.0582 19 e e 0.00360 15
FBAL % Fraction in BAL 0.980 0.3 e e e e
PROPPL % Proportional erroreplasma 45.9 12 24.8 7 25.3 15
ADDPL mg/L Additive erroreplasma e e 0.284 22 0.505 42
PROPLG % Proportional errorelung 43.5 13 18.1 25 46.1 30
PROPBAL % Proportional erroreBAL 38.0 22 e e e e
BAL, bronchoalveolar lavage; RSE, relative standard error.
a CL and V are apparent pharmacokinetic parameters following intratracheal administration and additive errors are expressed as variance.
b Parameters are scaled to 0.3 kg (typical weight of rats).
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Formulation Development
The solubility of SEN001, SEN019, and SEN032 in water and the
PP2% formulation is shown in Table 3. The compounds had poor
aqueous solubility and the measured equilibrium solubility values
ranged from <1 to 20.2 mg/mL. The PP2% formulation improved the
solubility of the drugs signiﬁcantly and increased the amount of
solubilized drugs to >180 mg/mL. In addition, PP2% did not cause
any detectable acute toxicity to the lungs of the animals, as sup-
ported by histological examination of the terminal lung samples.
PP2% was therefore used to deliver solubilized drugs for IT
administration in the PK studies.
Metabolic Stability
The metabolic stability results for SEN001, SEN019, and
SEN032 in human liver microsomes are shown in Table 4.
Overall, the results suggested that the metabolic stability of
SEN001 was superior to that of SEN019 and SEN032. SEN019 and
SEN032 were more likely to be rapidly cleared in vivo after
systemic absorption as a result of extensive metabolism, as
demonstrated by their high hepatic extraction ratios of 0.71 and
0.94, respectively.
Plasma Pharmacokinetics Following Pulmonary Administration
Following pulmonary administration, SEN001, SEN019, and
SEN032 were rapidly absorbed from lung to the plasma, as
demonstrated by the rapid appearance of the drugs in plasma
shortly after administration and the lack of a discernible absorption
phase in the plasma concentration-time proﬁles (Fig. 3). After ab-
sorption from the lung, the plasma concentrations of SEN001
declined steadily over the sampling period. In contrast, the con-
centrations of SEN019 and SEN032 in plasma declined more rapidly
and were below the LLOQ after 3 h and 6 h, respectively.
Lung Pharmacokinetics Following Pulmonary Administration
The concentrations of SEN001 in lung and BAL declined more
rapidly during the initial absorption and distribution into plasma
and deep lung tissue. After reaching distribution equilibrium at 2 h,
the decline in lung and BAL concentrations reﬂected the decline in
plasma concentrations during the elimination phase. The lung andBAL concentrations were closely correlated throughout the sam-
pling period. In contrast, the concentrations of SEN019 and SEN032
in the lung fell below the LLOQ after 1 h.
Pharmacokinetic Modeling
The observed concentrations of the 3 drugs were all well
described by the model with good predictive performance as
demonstrated in the VPC (Fig. 3). Although the deep lung
compartment (VLP) was needed to describe the observed con-
centrations for SEN001, the addition of a peripheral compartment
(VP) did not result in statistically signiﬁcant improvement in the
model ﬁt (ΔOFV ¼ 0.643). Neither the peripheral compartment
(VP) nor the deep lung compartment (VLP) was needed to describe
the observed concentrations for SEN019. In contrast, the four-
compartment disposition model best described the observed
concentrations for SEN032. The full model resulted in a statisti-
cally signiﬁcant improved model ﬁt compared to the reduced
models without either the peripheral compartment (VP) or the
deep lung compartment (VLP) (ΔOFV ¼ 9.054 and 10.47,
respectively).
The ﬁnal model described the drug concentration-time proﬁles
of the plasma, lung, and BAL samples, allowing direct comparison of
pharmacokinetic properties between the compounds with and
without BAL sampling. During model development, an additional
compartment was evaluated for the BAL samples, but this did not
reﬂect the drug disposition kinetics. In contrast, the observed
concentrations in the lung and BAL samples were best described
when the amounts of drug in the 2 samples were combined in the
central lung compartment and FBAL was estimated. The parameter
estimates of the ﬁnal model and the relative standard errors are
summarized in Table 5.
Predicted Lung and Plasma Exposure Following Different Dosing
Regimens
The concentrations of SEN001 in the lung before BAL
collection were calculated from the model, and a dose-
normalized exposure comparison was performed using the
predicted concentrations in lung and plasma following IT
administration of the 3 compounds every 24, 12, and 8 h
(Figs. 4 and 5). The predicted proﬁles indicated that the con-
centrations of SEN001 in lung before BAL collection were much
higher than those of the other 2 compounds. In contrast,
SEN019 and SEN032 were rapidly cleared from both lung and
Figure 4. The predicted drug concentration versus time proﬁles in lung showing the predicted median concentrations (line) and the corresponding 95% prediction intervals
(shaded) computed from the 1000 data sets in the simulated population with variability (CV of 30%) in central clearance (CLC) following intratracheal administration of SEN001,
SEN019, and SEN032 at 0.15 mg/kg every 24, 12, and 8 h (TAU).
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regimens. The predicted lung and plasma exposure to SEN019
and SEN032 remained much lower than that to SEN001
administered every 24 h, even after more frequent dosing (up
to every 12 and 8 h) and with variability in systemic clearance
being taken into account, as demonstrated by the substantially
lower area under the concentration-time curve (AUC) (Fig. 6).
In addition, the impact of systemic clearance on lung concen-
trations appeared to be limited. Although the variability in
plasma AUC resulting from the variability in central clearance
ranged from 28.6% to 31.6%, the variability in lung AUC
resulting from the same variability in central clearance ranged
from only 1.2% to 5.3%.Discussion
This study set out to investigate the pharmacokinetic properties
of 3 prototype QSIs, SEN001, SEN019, and SEN032, being developed
for the treatment of chronic PA lung infections, by collectively
analyzing the observed concentrations from the PK studies.
Because high local concentrations are desirable for treating lung
infections, we focused on comparing drug concentrations in the
lung following pulmonary administration. To remove the effect of
dissolution, a solution was selected as the formulation of choice.
Given the poor aqueous solubility of SEN001, chemical modiﬁca-
tions were made to reduce the lipophilicity of this compound. The
resulting SEN019 and SEN032 had, despite the lower logP, only
Figure 5. The predicted drug concentration versus time proﬁles in plasma showing the predicted median concentrations (line) and the corresponding 95% prediction intervals
(shaded) computed from the 1000 data sets in the simulated population with variability (CV of 30%) in central clearance (CLC) following intratracheal administration of SEN001,
SEN019, and SEN032 at 0.15 mg/kg every 24, 12, and 8 h (TAU).
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pulmonary formulation that effectively solubilized the compounds,
using excipients that have previously been used in the lung.24-26
Being the most soluble compound in water in the series, SEN019
appeared to interact least with the solubilizing agents and was the
least soluble compound of the 3 in the formulation. Nevertheless,
this PP2% formulation signiﬁcantly enhanced the solubility of the
compounds, allowing administration of the drugs in solution via
the pulmonary route. Consequently, drug dissolution and particle
clearance from the lung (e.g., mucociliary clearance) were not
considered in the model.The pharmacokinetic properties of the compounds following IT
administration were then investigated in rats. In the ﬁrst PK study,
SEN001was administered and drug concentrations in plasma, lung,
and BAL were evaluated. It was apparent that the drug was rapidly
absorbed from the lung, as demonstrated by its early appearance in
plasma. The large surface area and very thin alveolar epithelial
lining of the lung have long been suggested to allow rapid systemic
absorption.27-29 In fact, rapid systemic absorption from the lung,
with peak plasma concentrations reached in 5 min, has also been
observed after IT administration of other drugs.15,30-32 The plasma
concentration-time proﬁle of SEN001was consistent with the rapid
Figure 6. The area under the concentration-time curve (AUC) over 24 h computed from the predicted lung (top) and plasma (bottom) concentration-time proﬁles of the 1000 data
sets in the simulated population [means ± s.d.] following intratracheal administration of SEN001, SEN019, and SEN032 at 0.15 mg/kg every 24, 12, and 8 h (TAU).
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delivery.
The decline of SEN001 concentrations in the lung homogenate
and BAL samples mirrored its decline in the plasma samples after
distribution equilibrium at 2 h. The concentrations of SEN001 in the
lung and BAL samples were closely correlated throughout the
whole sampling period, suggesting colocation of the drug sampled
from the BAL and lung homogenate, with no kinetically discernible
distribution phase. The pharmacokinetic model strengthened this
hypothesis, since the addition of a separate distribution compart-
ment for drug amount in BAL did not improve the characterization
of the data. In contrast, the observed concentrations were well
described when the amounts of the drug in lung and BAL were
considered in the same compartment, and the distribution of drugs
into plasma and deep lung was dependent on the total amount of
drug in the central lung compartment. The fraction of the drug that
remained in the airway was then collected in BAL from the central
lung. Consequently, the model allowed quantiﬁcation of the drug
amount in the lung before BAL collection, and hence the direct
comparison of lung exposures to other compounds without BAL
sampling.Lung PK are typically investigated by collecting either lung ho-
mogenates from small animals for total lung exposures, ﬂuids from
the airways (e.g., BAL or sputum) as an indication of the amount of
drug in the epithelial lining ﬂuid, or microdialysis for drug con-
centrations at a speciﬁc site in the lung.13,15,16,31-34 While total lung
concentrations provide an estimate of overall lung exposure, they
might not always represent the most relevant therapeutic expo-
sure, since the amounts of intracellular and extracellular drugs are
indistinguishable from each other. Depending on the location of the
drug target, either intracellular or extracellular concentrations are
likely to be more applicable. Although BAL sampling is subject to
potential contaminationwith intracellular drugs released from cells
that rupture before or during the procedure, it can serve to provide
an initial indication of the amount of extracellular drug
concentration.
Although drug transfer between BAL and plasma has been
previously described using a modeling approach for the study of
other antibiotics and antituberculosis drugs,15,35-37 few studies in
the literature have simultaneously modeled and analyzed observed
drug concentration-time proﬁles of plasma, BAL, and lung ho-
mogenate samples collected from the same animals using a
T. Sou et al. / Journal of Pharmaceutical Sciences 108 (2019) 630-640 639quantitative approach. The results in the present study demon-
strate the close relationship between SEN001 concentrations in BAL
and the lung. The estimated fraction of SEN001 in BAL (FBAL) sug-
gested that most (>98%) of the SEN001 in the lung was likely
residing on the epithelial lining of the airways, instead of being
sequestrated intracellularly, before systemic absorption.
SEN019 and SEN032 were developed as structural analogues of
SEN001. Given the lack of a discernible distribution phase between
BAL and lung parenchyma for SEN001, BAL samples were not
collected for SEN019 and SEN032. The concentrations of these 2
compounds appeared to declinemore rapidly than those of SEN001.
In addition, the LLOQs for SEN019 and SEN032 in the lung samples
were different from that for SEN001, making direct comparisons of
drug concentration-time proﬁles difﬁcult. A pharmacokinetic
model was therefore developed, using all of the observed concen-
trations available, for the characterization and comparison of the
compound series.
Themodel described all of the concentration-time proﬁles of the
compound series following pulmonary administration, allowing
direct comparison of pharmacokinetic parameters between com-
pounds. Although all 3 compounds appeared in plasma shortly after
IT administration, SEN001 had the most favorable pharmacokinetic
properties for targeted treatment in the lung, with the longest
residence time in the lung after pulmonary administration, as
demonstrated by the slowest clearance from lung to plasma (CLLP)
and the additional deep lung compartment (VLP) in the model. In
contrast, the estimated CLLP of SEN032 was 107% and 757% higher
than that of SEN019 and SEN001, respectively. It seems likely that
SEN001, with the highest logP, distributed most widely into deep
lung tissue, resulting in the slowest clearance to plasma and the
longest residence time in the lung. Conversely, SEN019, with the
lowest logP, did not distribute extensively after delivery, as illus-
trated by the lack of deep lung and peripheral compartment in the
model, resulting in rapid elimination of the drug. In addition,
SEN032 was also most rapidly cleared following systemic absorp-
tion, as shown by the highest central clearance (CLC). These results
mirrored our ﬁndings on the metabolic stability of the compounds.
At ﬁrst glance, the peak lung concentrations of SEN001
appeared much lower than those of SEN019 and SEN032. However,
the SEN019 and SEN032 lung samples were analyzed directly,
without BAL sampling. To compare concentrations in lung and
plasma under standardized conditions, the model was used to
perform a dose-normalized exposure analysis, by comparing the
predicted drug concentrations in the lung and plasma following
pulmonary administration of the same dose every 24, 12, and 8 h.
Because the model allowed the estimation of lung concentrations
before BAL sampling, direct comparison of lung concentrations
between the compounds was possible. The results showed that
SEN001 would reach much higher local concentrations in the lung
after pulmonary administration compared to SEN019 and SEN032
(Figs. 4 and 5). Even after multiple dosing up to every 8 h, it was
unlikely that the lung and plasma exposures to SEN019 and SEN032
would be similar to SEN001 given every 24 h, as demonstrated by
the much lower predicted exposures (AUC) from the simulated
proﬁles (Fig. 6).
Although it is intuitive that physiological processes in the lung
(e.g., mucociliary clearance and absorption from the lung) could
impact on drugs available locally to treat lung infections, it is
difﬁcult to directly evaluate the inﬂuence of systemic clearance on
local drug exposure in the lung following pulmonary delivery.
Hence, drug exposures were predicted using the model with
variability in the central clearance (CLC) parameter to investigate
the speciﬁc impact of systemic clearance on lung concentrations
of the compounds. The results showed that systemic clearance
was unlikely to be the major factor impacting local drug exposurein the lung. It is therefore unlikely that the low SEN019 and
SEN032 exposures could be improved by reducing systemic
clearance. In contrast, lower systemic clearance could lead to a
much more inﬂuential increase in systemic drug exposure and
therefore an increased risk of systemic adverse effects. We
therefore suggest that novel QSIs designed for direct delivery to
the lung for targeted treatment of respiratory conditions should
ideally have long residence times in the lung for maximum local
exposure and efﬁcacy with rapid clearance after systemic ab-
sorption to reduce the risk of unwanted systemic adverse effects.
This design strategy is consistent with the approach advocated for
other local inhaled therapies such as inhaled corticosteroids,38-40
and the present study provides further quantitative insights into
the underlying drug dispositions resulting from such a delivery
strategy using a mathematical modeling approach. Similar design
principles should also be considered for local antimicrobial
therapies.
Although it is certainly of relevance to understand the PK of
newly synthesized compounds in healthy animals during the
candidate selection process, it should be noted that the local airway
conditions in CF lungs with chronic PA infection are quite different
compared to the ones in healthy animals. The presence of thick and
viscous mucus could potentially hinder the clearance of drugs from
the airways and alter their local PK proﬁles. In addition, the barriers
that bioﬁlms present to drug penetration to the microorganisms
could have implications on the local residence time required for
efﬁcacy. Nonetheless, the results of the present study provide
invaluable insights into the potential exposure of these compounds
following pulmonary delivery. To further explore their therapeutic
potential, studies to investigate the in vivo efﬁcacy of these com-
pounds in a relevant disease model would be beneﬁcial.
Conclusions
This study has demonstrated a number of applications where
pharmacometric modeling can be used as a powerful tool to inform
drug development for pulmonary delivery in a preclinical setting,
including the direct comparison of the pharmacokinetic properties
of compounds to facilitate drug candidate selection, the prediction
of in vivo exposure following different dosing regimens, and the
identiﬁcation of ideal pharmacokinetic properties to guide the
future development of the treatment. This is one of the few studies
reported in the literature inwhich drug concentration-time proﬁles
of BAL, lung homogenate, and plasma samples were modeled and
analyzed simultaneously to study lung PK. In addition, based on the
predicted drug exposures, we suggest that novel QSIs designed for
pulmonary delivery as targeted treatments for respiratory condi-
tions should ideally have long residence times in the lung for local
efﬁcacy, with rapid clearance after systemic absorption to reduce
the risk of unwanted systemic adverse effects. The developed
model can also be connected to an infection model to study drug
exposure-response relationships to improve the understanding of
the pharmacokinetic-pharmacodynamic relationships of QSIs.
Studies to develop QSIs as a novel treatment option for chronic PA
lung infections are currently being undertaken.
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